The NDA included data from two Phase 3 clinical trials (VENUS I and VENUS II), all four Phase 3 European Union registration studies, and real-world data of >700,000 women with uterine fibroids across 80 countries.
Researchers performed a cross-sectional study that included multiple year pooled data (2003 to 2011) from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS Outpatient Department).
Results showed an increased risk of bleeding with SRIs by 1.16-2.36 times with an even higher 3.17- to 10.9-fold risk with concomitant NSAIDs.
More than 9 million smokers have attempted to quit because of Tips from Former Smokers Campaign.
Greater reproducibility and higher concordance for melanoma staging with implementation of AJCC 8
Deficits similar for long-term type 1 diabetes and age-matched patients with type 2 diabetes
The FDA approval was supported by findings from a Phase 3, randomized, double-blind, placebo-controlled study that evaluated Imvexxy (4mcg and 10mcg) vs placebo from baseline to week 12.
Five percent of children uninsured in 2017, 41.3 and 55.0% had public and private coverage.
High-certainty evidence for protection in adolescent girls and young women aged 15 to 26 years
Risk not increased for non-advanced adenoma found on colonoscopy following flex sigmoidoscopy
